Wall Street Zen upgraded shares of Apnimed (NASDAQ:APMD – Free Report) to a hold rating in a research report report published on Saturday morning.
Apnimed Stock Performance
Shares of NASDAQ:APMD opened at $27.00 on Friday. Apnimed has a one year low of $16.12 and a one year high of $29.15.
Insider Buying and Selling
In other Apnimed news, major shareholder Morningside Venture Investment bought 312,500 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was bought at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the transaction, the insider owned 7,152,713 shares of the company’s stock, valued at approximately $114,443,408. The trade was a 4.57% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Apnimed Company Profile
Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.
Featured Articles
- Five stocks we like better than Apnimed
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Apnimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed and related companies with MarketBeat.com's FREE daily email newsletter.
